We also investigated the possibility that C1632 acts as a small molecule anticancer drug targeting both LIN28 and FGFR1 in the treatment of NSCLC, especially for cisplatin‐resistant NSCLC. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.